greeksoup/ stock research

Maximus, Inc.: Q4 FY2026 earnings call

What management said about Q4 FY2026, from the documents filed with the SEC on 19 November 2026: press release. Guidance figures: 13 new. The quarter’s numbers.

Key takeaways

  • Full-year revenue declined from prior year: Fiscal 2026 revenue was $5.23 billion, down from $5.43 billion. Management said fiscal 2025 had benefited from disaster support and clinical volume surges that did not recur at the same level. Source
  • Margins rose on productivity: Operating margin was 11.7% against 9.7%, and adjusted EBITDA margin 14.2% against 12.9%. Management attributed the improvement to technology-enabled productivity, automation and cost management. Source
  • Adjusted EPS above top of guidance: Adjusted diluted EPS was $8.24 against $7.36, up 12.0%, and above the top end of the most recently updated guidance range. Diluted EPS was $7.27 against $5.51. Source
  • Signed awards and pending contracts: Signed fiscal 2026 awards were $2.51 billion. Awarded but unsigned contracts stood at $1.86 billion at September 30, 2026. Source
  • Large state Medicaid renewal signed: The renewal enabled the quarter's book-to-bill. Two further state Medicaid renewals of about $528 million total contract value sit in the contracts pending balance. Source
  • Full-year operating and free cash flow: Operating cash flow was $112 million and free cash flow $69 million, against $429 million and $366 million a year earlier. Fourth-quarter free cash flow was $278 million. Source
  • Agile Defense acquisition completed November 18: Maximus completed the Agile Defense acquisition on November 18, 2026. Agile Defense serves the Department of War, Intelligence Community, homeland security and civilian agencies. Source
  • Fiscal 2027 revenue guidance: Fiscal 2027 revenue is guided at $5.45 billion to $5.65 billion, including about ten months of Agile Defense contribution. Source
  • EPS guidance excludes fiscal 2026 incentive: Fiscal 2026 included about $75 million of incentive revenue and $1.05 of adjusted EPS. Excluding that contribution, the guidance midpoint represents growth of about 8%. Source

“Fiscal year 2026 reflected the benefits of disciplined execution, technology-enabled productivity enhancements, and thoughtful capital allocation,”

Bruce Caswell, President and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceFiscal year 2027$5.45 billion to $5.65 billionNew
Adjusted EBITDA SourceFiscal year 2027$690 million to $725 millionNew
Adjusted EBITDA margin SourceFiscal year 2027approximately 12.8%New
Net income SourceFiscal year 2027$320 million to $346 millionNew
Diluted EPS SourceFiscal year 2027$6.15 to $6.65New
Adjusted diluted EPS SourceFiscal year 2027$7.50 to $8.00New
Free cash flow SourceFiscal year 2027$700 million to $800 millionNew
Capital expenditures SourceFiscal year 2027$45 millionNew
Amortization of intangible assets SourceFiscal year 2027approximately $96 millionNew
Depreciation and amortization of property, equipment and capitalized software SourceFiscal year 2027approximately $55 millionNew
Interest expense SourceFiscal year 2027approximately $110 millionNew
Effective tax rate SourceFiscal year 2027approximately 25%New
Weighted average shares outstanding SourceFiscal year 2027approximately 52.1 millionNew

What changed from last quarter

  • New guidance: Management established fiscal 2027 guidance, which excludes a fiscal 2026 program benefit. Source
  • New: The Agile Defense acquisition, announced in October 2026 with closing expected in the first quarter of fiscal 2027, was completed after fiscal year-end. Source
  • Ended: Fiscal 2027 guidance assumes no VA MDE incentive contribution, which fiscal 2026 included. Source

Full-year results and margins

  • Full-year revenue declined from prior year: Fiscal 2026 revenue was $5.23 billion, down from $5.43 billion. Management said fiscal 2025 had benefited from disaster support and clinical volume surges that did not recur at the same level. Source
  • Margins rose on productivity: Operating margin was 11.7% against 9.7%, and adjusted EBITDA margin 14.2% against 12.9%. Management attributed the improvement to technology-enabled productivity, automation and cost management. Source
  • Adjusted EPS above top of guidance: Adjusted diluted EPS was $8.24 against $7.36, up 12.0%, and above the top end of the most recently updated guidance range. Diluted EPS was $7.27 against $5.51. Source

U.S. Federal Services

  • Federal revenue fell on prior surges: Federal Services revenue was about $2.99 billion against $3.07 billion. Management said the prior year included nearly $100 million of disaster and clinical surges that did not recur at the same level. Source
  • Federal margin rose to 18.1%: Segment operating margin was 18.1% against 15.3%. Management cited automation, productivity, operating leverage and VA MDE incentive payments in the first three quarters. Source
  • Fourth-quarter VA MDE modification: Fourth-quarter results reflected a previously disclosed customer-directed modification to VA MDE performance incentives, which management noted in the results. Source

“Throughout the year, we continued deploying automation and AI-enabled solutions across our operations, improving efficiency, strengthening profitability, and delivering meaningful outcomes for customers.”

Bruce Caswell, President and Chief Executive Officer

U.S. Services

  • Services revenue fell, margin 9.1%: U.S. Services revenue was $1.68 billion against $1.76 billion, and segment margin was 9.1% against 9.7%. Management said volumes varied across several contract areas. Source
  • Positive organic growth in fourth quarter: Management said revenue trends improved through fiscal 2026 and reached positive organic growth in the fourth quarter. Source
  • Impairment and state demand indicators: A $6.9 million non-cash impairment was taken on a software asset built for one customer. Management described Medicaid and state program demand indicators as encouraging. Source

Outside the U.S.

  • Outside U.S. revenue declined to $557M: Revenue was $557 million against $600 million. Management attributed the decline to previously divested businesses and lower revenue in several employment services and clinical programs. Source
  • Segment posted modest operating loss: The segment reported a modest operating loss, which management tied mainly to lower revenue in employment services and clinical programs. Source
  • Disciplined bid selection and conversion: Management said it continues to pursue profitable growth through disciplined bid selection, operational improvements and conversion of its sales pipeline. Source

“These efforts contributed to adjusted diluted earnings per share of $8.24, representing 12.0% growth over the prior year and performance above the top end of our most recently updated guidance range.”

Bruce Caswell, President and Chief Executive Officer

Sales pipeline and awards

  • Signed awards and pending contracts: Signed fiscal 2026 awards were $2.51 billion. Awarded but unsigned contracts stood at $1.86 billion at September 30, 2026. Source
  • Book-to-bill near 1.0x in fourth quarter: The trailing twelve-month book-to-bill ratio was 0.5x. The quarterly ratio improved to approximately 1.0x. Source
  • Large state Medicaid renewal signed: The renewal enabled the quarter's book-to-bill. Two further state Medicaid renewals of about $528 million total contract value sit in the contracts pending balance. Source

Cash, balance sheet and shareholder returns

  • Full-year operating and free cash flow: Operating cash flow was $112 million and free cash flow $69 million, against $429 million and $366 million a year earlier. Fourth-quarter free cash flow was $278 million. Source
  • Major customer paid after year-end: More than $330 million was collected from a major customer through November 13, 2026, as anticipated in fiscal 2026 guidance. Source
  • DSO fell to 93 days: DSO was 93 days at September 30, 2026, against 98 days at June 30, 2026. Source
  • Leverage at 1.8x, 2.3x pro forma: Gross debt was $1.61 billion and cash $280 million. Pro forma for Agile Defense, leverage is expected at about 2.3x, within the 2x to 3x target range. Source
  • Share repurchases and dividend: About 2.6 million shares were repurchased for about $192 million, and $400 million remains under the latest authorization. A $0.33 quarterly dividend was declared October 5, 2026. Source

Agile Defense acquisition

  • Agile Defense acquisition completed November 18: Maximus completed the Agile Defense acquisition on November 18, 2026. Agile Defense serves the Department of War, Intelligence Community, homeland security and civilian agencies. Source
  • Cash purchase price of $660 million: The October 2026 agreement set a cash purchase price of $660 million payable at closing, subject to adjustments, plus possible contingent consideration tied to performance objectives.
  • Expands defense and national security reach: Management said the deal adds cybersecurity, digital modernization, software, analytics, cloud and AI-enabled mission support capabilities to defense and national security work. Source

Fiscal 2027 guidance and assumptions

  • Fiscal 2027 revenue guidance: Fiscal 2027 revenue is guided at $5.45 billion to $5.65 billion, including about ten months of Agile Defense contribution. Source
  • EPS guidance excludes fiscal 2026 incentive: Fiscal 2026 included about $75 million of incentive revenue and $1.05 of adjusted EPS. Excluding that contribution, the guidance midpoint represents growth of about 8%. Source
  • Adjusted EBITDA margin about 12.8%: Adjusted EBITDA margin is expected at approximately 12.8% in fiscal 2027, with adjusted diluted EPS of $7.50 to $8.00. Source

Earnings drivers and cost base

  • Earnings growth from margins and buybacks: Management attributed earnings growth principally to improved operating performance and to share repurchases. Source
  • SG&A declined year over year: Full-year SG&A was $681.3 million, down from $713.1 million. Source
  • Amortization of intangibles declined: Amortization of intangible assets was $81.2 million for the year, down from $92.0 million, and $20.4 million for the quarter. Source

Coming up, as management said on 19 November 2026

  • Dividend of $0.33 payable November 30: The quarterly dividend is payable on November 30, 2026, to holders of record on November 13, 2026. Source

Figures management reported

FigureReported
Signed contract awards, fiscal 2026 Source$2.51 billion
Contracts pending (awarded but unsigned) Source$1.86 billion
Total sales pipeline Source$44.8 billion
Recompete win rate, fiscal 2026 Sourceapproximately 89%

Risks management discussed

  • Operational: Management named integration of Agile Defense as a focus for fiscal 2027, alongside growing existing customer relationships. Source
  • Financial: Management said some fiscal 2026 cash generation moved into fiscal 2027 for timing reasons rather than collection concerns. Source
  • Demand: Outside the U.S. revenue reflects customer-specific challenges in several employment services and clinical programs. Source
  • Demand: Management expects clinical portfolio performance to moderate in fiscal 2027 after a strong fourth quarter. Source

Earlier plans management reported on

  • Met: Management said fiscal 2026 revenue finished within the guidance range and was consistent with expectations through the year. Source
  • Met: The October 2026 announcement expected closing in the first quarter of fiscal 2027; the acquisition was completed November 18, 2026.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.